产品
编 号：F193291
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1612838-76-2
产品详情
生物活性：
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.
体内研究：
Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production.Animal Model:Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days)
Dosage:1 mg/kg
Administration:i.p.; single dosage
Result:Significantly inhibited IL23-induced ear swelling and cytokine production.
Animal Model:Cynomolgus monkeys
Dosage:1.0 mg/kg
Administration:i.v. or s.c.
Result:Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys.IV (1 mg/kg) SC (1 mg/kg)
AUCinf (μg·day/mL)202 ± 33.5142 ± 33.3
CL (mL/day/kg)5.18 ± 0.8/
Vd, ss (mL/kg)88.3 ± 3.12/
t1/2 (h)12.2 ± 2.28/9.15 ± 1.87
Cmax (μg/mL)/10.1 ± 3.14
Tmax (day)/2.11 ± 1.84
F (%)/70.4 ± 16.5
体外研究：
Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with Kds Risankizumab 相关抗体:
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.
体内研究：
Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production.Animal Model:Mice (injected with BI 655066, 1 h later injected recombinant human IL23 into the skin of the mouse ear for 4 days)
Dosage:1 mg/kg
Administration:i.p.; single dosage
Result:Significantly inhibited IL23-induced ear swelling and cytokine production.
Animal Model:Cynomolgus monkeys
Dosage:1.0 mg/kg
Administration:i.v. or s.c.
Result:Pharmacokinetic Parameters of Risankizumab (BI 655066) in cynomolgus monkeys.IV (1 mg/kg) SC (1 mg/kg)
AUCinf (μg·day/mL)202 ± 33.5142 ± 33.3
CL (mL/day/kg)5.18 ± 0.8/
Vd, ss (mL/kg)88.3 ± 3.12/
t1/2 (h)12.2 ± 2.28/9.15 ± 1.87
Cmax (μg/mL)/10.1 ± 3.14
Tmax (day)/2.11 ± 1.84
F (%)/70.4 ± 16.5
体外研究：
Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with Kds Risankizumab 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备